WO1997026784B1 - Induction of immune response against desired determinants - Google Patents
Induction of immune response against desired determinantsInfo
- Publication number
- WO1997026784B1 WO1997026784B1 PCT/US1997/001041 US9701041W WO9726784B1 WO 1997026784 B1 WO1997026784 B1 WO 1997026784B1 US 9701041 W US9701041 W US 9701041W WO 9726784 B1 WO9726784 B1 WO 9726784B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- aaxvaaatlkaaa
- immune response
- aaxaaakt
- aaxaaaatlkaaa
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title claims abstract 6
- 230000001939 inductive effect Effects 0.000 title claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 8
- 230000004044 response Effects 0.000 claims abstract 2
- 229960000310 ISOLEUCINE Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 3
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2S)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000890 antigenic Effects 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229960003767 Alanine Drugs 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229960005190 Phenylalanine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 150000004676 glycans Polymers 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 150000004804 polysaccharides Polymers 0.000 abstract 1
Abstract
The present invention provides compositions and methods of inducing immune response in patients. In particular, it provides compositions useful in inducing humoral responses against desired immunogens, particularly polysaccharides.
Claims
AMENDED CLAIMS
[received by the International Bureau on 5 August 1997 (05.08.97); original claim 25 amended; remaining claims unchanged (2 pages)] 25 The composition of claim 18, wherein the PADRE peptide is selected from the group consisting of AAXAAAKT AAAAA, AAXAAAATLKAAA, AAXVAAATLKAAA AAXVAAATLKAAA AAXIAAATLKAAA AKXVAAWTLKAAA, and AKFVAAWTLKAAA wherein A is L-Alanine. X is cyclohexylaianine. K is lysine, T is threonine, L is leucine, V is vaiine. I is isoleucine. W is tryptophan, and F is phenylalanine
26 The composition of claim 18, wherein the PADRE peptide is selected from the group consisting of AAXAAAKT AAAAa, AAXAAAATLKAAa, AAXVAAATLKAAa. AAXVAAATLKAAa, AAXJAAATLKAAa, AKXVAAWTLKAAa, and AKFVAAWTLKAAa wherein a is D-aiamne, A is L-Alanme, X is cvciohexvlalanme. K is lysine, T is threonine, L is leucine, V is valine, I is isoleucine, W is tryptophan, and F is phenvlalanine
27 The composition of claim 18, wherein the PADRE peptide is selected from the group consisting of aAXAAAKT AAAAA, aAXAAAATLKAAA, aAXVAAATLKAAA aAXVAAATLKAAA, aAXIAAATLKAAA, aKXVAAWTLKAAA and aKFVAAWTLKAAA wherein a is D-alanme, A is L-Alanme, X is cyclohexyialaninε. K is lysine. T is threonine. L is leucine, V is valine, I is isoleucine. W is tryptophan. and F is phenvlalanine
28 A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a non-proteinaceous antigenic determinant and a PADRE oiigopeptiαe of less than about 50 residues
29 The composition of claim 28. further comprising an adiuvant
30 The composition of claim 29. wherein the adiuvant is Freund s complete adjuvant or Freund's incomplete adjuvant
31 A method of inducing a humorai immune response comDπsing introduction into a mammal the composition of claim 28
78
32. The method of claim 31 , wherein the introduction is parenteral
33. The method of claim 31, wherein the immune response is prophylactic.
34. The method of claim 31 , wherein the immune response is therapeutic.
35. The method of claim 31, wherein the immune response comprises an IgG response directed against the antigenic determinant of claim 1
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK97902074T DK0876398T3 (en) | 1996-01-24 | 1997-01-23 | Induction of immune response with desired determinants |
| BR9710404A BR9710404A (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
| CA2242878A CA2242878C (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
| AU15827/97A AU1582797A (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
| JP52697997A JP4063879B2 (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
| EP97902074A EP0876398B1 (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
| AT97902074T ATE220687T1 (en) | 1996-01-24 | 1997-01-23 | THE GENERATION OF AN IMMUNE RESPONSE AGAINST DESIRED DETERMINANTS |
| DE69714011T DE69714011T2 (en) | 1996-01-24 | 1997-01-23 | THE GENERATION OF AN IMMUNE RESPONSE TO DESIRED DETERMINANTS |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1051096P | 1996-01-24 | 1996-01-24 | |
| US60/010,510 | 1996-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997026784A1 WO1997026784A1 (en) | 1997-07-31 |
| WO1997026784B1 true WO1997026784B1 (en) | 1997-11-06 |
Family
ID=21746084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/001041 WO1997026784A1 (en) | 1996-01-24 | 1997-01-23 | Induction of immune response against desired determinants |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0876398B1 (en) |
| JP (1) | JP4063879B2 (en) |
| CN (1) | CN1214051A (en) |
| AT (1) | ATE220687T1 (en) |
| AU (1) | AU1582797A (en) |
| BR (1) | BR9710404A (en) |
| CA (1) | CA2242878C (en) |
| DE (1) | DE69714011T2 (en) |
| DK (1) | DK0876398T3 (en) |
| ES (1) | ES2177927T3 (en) |
| PT (1) | PT876398E (en) |
| WO (1) | WO1997026784A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528061B1 (en) * | 1997-09-04 | 2003-03-04 | Pasteur Institut | Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions |
| EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
| WO2004052930A2 (en) * | 2002-12-11 | 2004-06-24 | Pharmexa A/S | Targeting single epitopes |
| WO2004094454A2 (en) | 2003-04-18 | 2004-11-04 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
| ES2310072B1 (en) | 2005-12-23 | 2009-11-16 | Proyecto De Biomedicina Cima, S.L. | NEW ANTIGENIC DETERMINING PEPTIDES T COLLABORATORS (/ DTH) |
| WO2009025777A1 (en) * | 2007-08-17 | 2009-02-26 | University Of Maryland | Carbohydrate functionalized catanionic surfactant vesicles for drug delivery |
| WO2010086294A2 (en) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
| WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
| RU2668560C2 (en) | 2013-03-29 | 2018-10-02 | Сумитомо Дайниппон Фарма Ко., Лтд. | Conjugate vaccine on basis of antigen wt1 peptide |
| WO2014157704A1 (en) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Conjugate vaccine using trimming function of erap1 |
| WO2015017734A1 (en) | 2013-07-31 | 2015-02-05 | Board Of Trustees Of The University Of Arkansas | Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens |
| JP2017518958A (en) * | 2014-03-19 | 2017-07-13 | マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ | Antibodies against immunogenic glycopeptides, compositions containing them, and uses thereof |
| CN107141355B (en) * | 2017-05-31 | 2021-05-14 | 中国人民解放军第四军医大学 | HTNV (human immunodeficiency Virus) antigen epitope linear tandem polypeptide, epitope peptide-compound tetramer and application |
| CN109991422A (en) * | 2017-12-29 | 2019-07-09 | 复旦大学 | The detection method of palmitoylation modification protein based on specific corrosioning anteserum |
| WO2021228853A1 (en) | 2020-05-11 | 2021-11-18 | Ose Immunotherapeutics | Vaccine against sars-cov virus |
| KR102261457B1 (en) * | 2020-07-22 | 2021-06-09 | (주)쓰리에이치바이오 | A peptide used for Immunotherapeutics |
| BR112023000620A2 (en) | 2020-07-22 | 2023-03-28 | 3H Bio Co Ltd | PEPTIDE USED FOR IMMUNOTHERAPEUTICS |
| WO2022268916A2 (en) | 2021-06-23 | 2022-12-29 | Ose Immunotherapeutics | Pan-coronavirus peptide vaccine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960700739A (en) * | 1993-03-05 | 1996-02-24 | 카린 이스텀 | HLA-A2. 1 binding peptide and uses thereof (HLA-A2.1 BINDING PEPTIDES AND THEIR USES) |
| CN1135181A (en) * | 1993-09-14 | 1996-11-06 | Cytel有限公司 | Alteration of immune response using pan Dr-binding peptides |
-
1997
- 1997-01-23 EP EP97902074A patent/EP0876398B1/en not_active Expired - Lifetime
- 1997-01-23 JP JP52697997A patent/JP4063879B2/en not_active Expired - Lifetime
- 1997-01-23 BR BR9710404A patent/BR9710404A/en not_active IP Right Cessation
- 1997-01-23 AT AT97902074T patent/ATE220687T1/en active
- 1997-01-23 CA CA2242878A patent/CA2242878C/en not_active Expired - Lifetime
- 1997-01-23 ES ES97902074T patent/ES2177927T3/en not_active Expired - Lifetime
- 1997-01-23 CN CN97193221A patent/CN1214051A/en active Pending
- 1997-01-23 DE DE69714011T patent/DE69714011T2/en not_active Expired - Lifetime
- 1997-01-23 WO PCT/US1997/001041 patent/WO1997026784A1/en active IP Right Grant
- 1997-01-23 PT PT97902074T patent/PT876398E/en unknown
- 1997-01-23 DK DK97902074T patent/DK0876398T3/en active
- 1997-01-23 AU AU15827/97A patent/AU1582797A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997026784B1 (en) | Induction of immune response against desired determinants | |
| CA2242878A1 (en) | Induction of immune response against desired determinants | |
| US6713301B1 (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens | |
| AU764961B2 (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides | |
| JP2009108097A (en) | Peptide with increased binding affinity for hla molecule | |
| EP0804158A4 (en) | Compositions and methods for eliciting ctl immunity | |
| CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
| EP1847549A3 (en) | Papillomavirus polyprotein constructs | |
| RU98101249A (en) | OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE | |
| AU5711294A (en) | Novel proteinaceous particles | |
| CA2331258A1 (en) | Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220 | |
| ATE397068T1 (en) | ANTIGEN MENINGOCOCCAL PEPTIDES | |
| DE69534617D1 (en) | Hepatitis b-impfstoff | |
| AU5533490A (en) | Synthetic (pseudomonas) (aeruginosa) pilin peptide and related vaccines and diagnostics | |
| CA2129747A1 (en) | Peptide for diagnosing and immunizing against t. cruzi infection | |
| US20050049197A1 (en) | Induction of immune response against desired determinants | |
| AU7237391A (en) | Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine | |
| EP0954529A4 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
| CA2337754A1 (en) | Recombinant multivalent malarial vaccine against plasmodium falciparum | |
| MX2022014649A (en) | A peptide cocktail. | |
| EP0596959A4 (en) | Self-adjuvanting peptide vaccine delivery system and production thereof. | |
| CA2082425A1 (en) | Vaccine compositions | |
| DE69626642T2 (en) | CETP FOR INCREASING THE HDL CHOLESTEROL CONTENT | |
| WO1993014206A3 (en) | Synthetic peptides for a rubella vaccine | |
| WO1997039029A3 (en) | An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof |